TABLE 3.

Pharmacokinetic parameters for atazanavir and ritonavir on week 2 (atazanavir-ritonavir) and week 6 (with addition of tenofovir)^a

Drug and time	Cmax (ng/ml)	Tmax (h)b	C0 (ng/ml)	Clast (ng/ml)	Cmin (ng/ml)	AUC0-t (ng · h/ml)	AUC0-24 (ng · h/ml)	Carc (ng/ml)	CLo (ml/min)	t1/2 (h)
Atazanavir
Wk 2	5,233 ± 3,033	3 (2-5)	1,571 ± 2,524	924 ± 829	862 ± 838	53,634 ± 35,255	53,761 ± 35,294	2,240 ± 1,471	123 ± 61	8.6 ± 2.3
Wk 6	3,443 ± 1,412	5 (1-5)	685 ± 417	665 ± 559	577 ± 367	39,231 ± 23,035	39,276 ± 23,034	1,636 ± 960	164 ± 84	8.6 ± 3.1
Rc (90% CI)	0.72 (0.50-1.05)				0.77 (0.54-1.10)		0.75 (0.58-0.97)
P	0.06				0.22		0.05
Ritonavir
Wk 2	940 ± 336	3 (2-8)	60 ± 37	59 ± 37	50 ± 31	7,541 ± 3,226	7,546 ± 3,226	314 ± 134	255 ± 98	5.1 ± 0.7
Wk 6	812 ± 447	3 (0-5)	52 ± 22	53 ± 39	42 ± 19	6,575 ± 4,041	6,603 ± 3,999	275 ± 167	507 ± 737	5.3 ± 0.7
R (90% CI)	0.72 (0.43-1.21)				0.91 (0.73-1.13)		0.75 (0.44-1.24)
P	0.38				0.42		0.41

^aData are expressed as means ± standard deviations unless indicated otherwise.

^bData are expressed as medians (ranges).

^cR is the ratio of the geometric means for the parameters at week 6 to those at week 2.